2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 540

Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Abstract Number: 1400

Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis
Abstract Number: 1796

Benefits and Sustainability of a Learning Collaborative for Implementation of Treat to Target in Rheumatoid Arthritis: Results of Phase II of a Cluster Randomized Controlled Trial
Abstract Number: 45

BIIB063, a Potent Anti-CD40 Antagonistic Monoclonal Antibody (MAb): Lessons Learned from an Early Development Program.
Abstract Number: 299

Bik Plays an Important Role of Cell Proliferation Caused By Nitric Oxide in Rheumatoid Arthritis Synovium
Abstract Number: 2397

Bilateral Femoral DXA Scan in Patients with Rheumatoid Arthritis
Abstract Number: 1936

Bimekizumab Blocks T Cell-Mediated Osteogenic Differentiation of Periosteal Stem Cells: Coupling Pathological Bone Formation to IL-17A and IL-17F Signaling
Abstract Number: 1571

Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Abstract Number: 307

Biochemical Intervertebral Disc Alterations in Patients with Low Back Pain and Radiculopathy
Abstract Number: 922

Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis
Abstract Number: 2278

Biologic Switching Among JIA Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1046

Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Abstract Number: 1562

Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Abstract Number: 2405

Biological Function Integrated Prediction of Severe Radiographic Progression in Rheumatoid Arthritis: A Nested Case Control Study
Abstract Number: 2332

Biomarkers for the Diagnosis and the Identification of Risk of Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].